

IMJUDO
(tremelimumab-actl)

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Unresectable hepatocellular carcinoma (uHCC)
 - a. Used in combination with durvalumab
2. Metastatic non-small cell lung cancer (NSCLC)
 - a. **NO** sensitizing EGFR or ALK genomic tumor aberrations
 - b. Used in combination with durvalumab and platinum-based chemotherapy

AND ALL of the following:

- a. Prescriber agrees to monitor for immune-mediated reactions
- b. Prescriber agrees to monitor liver enzymes, adrenocorticotrophic hormone (ACTH), and thyroid function at baseline and before each dose
- c. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Imjudo and for 3 months after the last dose

Prior - Approval Limits

Duration 12 months

Prior – Approval *Renewal* Requirements

None

Prior - Approval *Renewal* Limits

None